drugset / Trial / NCT06789848
Ligufalimab and Cadonilimab in Advanced Liver Cancers
Phase 2
Recruiting
64 enrolled
University of Texas Southwestern Medical Center
Akesobio · collabJosephine Hughes Sterling Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.
Timeline
- Start
- 2025-02-18
- Primary completion
- 2029-05-31
- Completion
- 2030-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK117 | Monoclonal antibody | 45 mg/kg | Intravenous |
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |